Material Agreement Form 8 K

On July 11, 2024, BioXcel Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Commercial Supply Agreement, dated as of April 1, 2022, with ARx, LLC ("ARx"). The Amendment reduces the specified minimum annual payment payable by the Company to ARx over the next three years starting in 2024 and, thereafter, for a specified interval, provides for minimum annual payments to the extent that the Company receives approval of a supplemental new drug application (sNDA) or a new drug application (NDA) from the U.S. Food and Drug Administration for enumerated indications.